Skip to main content
Toggle navigation
Search
Home
Browse by Poster Title
Home
Browse by Poster Title
Browse by Poster Title
Type here to filter the list
All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
#
Sort by
#
Sort by
Title
A
PII-041
A CASE OF HEPATOTOXICITY DURING COMBINATION AXITINIB AND PEMBROLIZUMAB THERAPY IN A CYP3A4 AND CYP3A5 DUAL POOR METABOLIZER
Favorite
PII-122
A COMPUTATIONAL PLATFORM TO SUPPORT THE DEVELOPMENT OF MRNA-BASED VACCINES AND THERAPEUTICS.
Favorite
PI-022
A CRISPR/CAS9-DERIVED ABCB1/ABCG2 KNOCKOUT PLATFORM FOR SUBSTRATE CHARACTERIZATION.
Favorite
PI-001
A LANDSCAPE SURVEY FOR THE PRESENTATIONS APPROVED FOR SUBCUTANEOUS PROTEIN PRODUCTS.
Favorite
PII-109
A LITERATURE REVIEW OF DRUG-DRUG-DISEASE INTERACTION IN PATIENTS WITH HEPATIC OR RENAL IMPAIRMENT.
Favorite
PI-123
A MECHANISTIC QUANTITATIVE SYSTEMS PHARMACOLOGY FRAMEWORK FOR MODEL-INFORMED TRANSLATIONAL ASSESSMENT OF MESENCHYMAL STEM CELL THERAPY IN LUPUS NEPHRITIS
Favorite
PI-052
A MODELING APPROACH TO EXPEDITE THE DEVELOPMENT OF A NEW LONG-ACTING CONTROLLED-RELEASE MULTIPURPOSE FORMULATION CONTAINING MEDROXYPROGESTRONE ACETATE
Favorite
PII-053
A NOVEL MODELING APPROACH FOR PREDICTING THE TIME COURSE OF ANTI-DRUG ANTIBODIES OF BIOLOGICS: APPLICATION TO AXATILIMAB AS AN EXAMPLE
Favorite
LB-010
A PHARMACOLOGY AND PHYSIOLOGY ENABLED MACHINE LEARNING MODEL FOR PHARMACOKINETICS OF ANTIBODY-BASED THERAPEUTICS
Favorite
PI-053
A PHASE 1 MICROTRACER STUDY EVALUATING THE MASS BALANCE, EXCRETION, AND PHARMACOKINETICS OF [14C]-GBT021601, AN ORAL SICKLE HEMOGLOBIN POLYMERIZATION INHIBITOR, IN HEALTHY PARTICIPANTS.
Favorite
PI-110
A PHASE 1, MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF A SINGLE DOSE OF RIMEGEPANT IN CHILDREN (>=6 TO <12 YEARS OF AGE) WITH A HISTORY OF MIGRAINE
Favorite
PII-054
A PHASE 1, OPEN-LABEL STUDY IN HEALTHY MALE SUBJECTS OF THE ABSORPTION, METABOLISM, EXCRETION, AND PHARMACOKINETICS OF SEVASEMTEN
Favorite
PI-054
A PHASE 1, OPEN-LABEL, SINGLE-DOSE, PARALLEL DESIGN, STUDY TO EVALUATE PHARMACOKINETIC COMPARABILITY OF TWO PF-07940367 FILM-COATED TABLET FORMULATIONS ADMINISTERED AS 150 MG UNDER FASTED CONDITIONS IN HEALTHY PARTICIPANTS
Favorite
E-003
A QUANTITATIVE SYSTEMS PHARMACOLOGY QSP) MODEL FRAMEWORK FOR COMBINED CLINICAL EFFICACY AND HEMATOLOGICAL TOXICITY PRECITIONS FOR ANTIBODY DRUG CONJUGATES.
Favorite
PII-055
A RANDOMIZED, THREE-PERIOD, CROSSOVER STUDY OF SINGLE AND REPEATED DOSES OF ELIGLUSTAT IN HEALTHY PARTICIPANTS, CYP2D6 EXTENSIVE AND POOR METABOLIZERS
Favorite
PI-055
A SEMI-MECHANISTIC PHARMACOKINETIC/PHARMACODYNAMIC (PK/PD) MODEL OF ABBV-383 CHARACTERIZING THE INTERPLAY BETWEEN SOLUBLE BCMA (SBMCA) AND FREE AND TOTAL PK.
Favorite
PII-115
A SIMPLE AND SENSITIVE ULTRA-HIGH PERFORMANCE LIQUID CHROMATOGRAPHY TANDEM MASS SPECTROMETRY (UHPLC-MS/MS) ASSAY TO QUANTIFY TIZANIDINE AND ITS METABOLITES IN HUMAN PLASMA
Favorite
PII-123
A STUDY ON THE PREVALENCE OF CHRONIC CANNABINOID USE INDUCING HYPEREMESIS SYNDROME
Favorite
PI-026
A STUDY TO EVALUATE RELATIVE BIOAVAILABILITY OF THREE NAPAROFENIB (LXH254) FORMULATIONS IN HEALTHY SUBJECTS
Favorite
PI-011
ABSORPTION OF ELIGLUSTAT VIA THE BUCCAL CAVITY FOLLOWING ORAL ADMINISTRATION OF ELIGLUSTAT SOLUTION IN HEALTHY ADULT PARTICIPANTS.
Favorite
PII-056
ADME PROFILING OF TARGETED ORAL PEPTIDE JNJ-77242113
Favorite
PWI-003
ADVANCEMENTS IN PEDIATRIC PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODELING OF DRUGS IN LACTATION FOR GUIDING NEONATAL EXPOSURE RISK ASSESSMENT
Favorite
PT-015
ADVANCEMENTS IN PEDIATRIC PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODELING OF DRUGS IN LACTATION FOR GUIDING NEONATAL EXPOSURE RISK ASSESSMENT
Favorite
PT-018
AI/ML DERIVED MAGNETIC RESONANCE BIOMARKERS FOR BONE FRAGILITY IN DUCHENNE MUSCULAR DYSTROPHY
Favorite
OAII-001
AI/ML DERIVED MAGNETIC RESONANCE BIOMARKERS FOR BONE FRAGILITY IN DUCHENNE MUSCULAR DYSTROPHY
Favorite
PI-056
ALTERNATIVE DOSING GUIDELINES TO IMPROVE OUTCOMES IN MULTIDRUG-RESISTANT TUBERCULOSIS.
Favorite
PII-057
AN AUTOMATED COMPARISON PLATFORM FOR INFORMED DRUG LABELING DECISIONS: WEIGHT-BASED DOSING VS. WEIGHT-BANDED DOSING.
Favorite
PI-124
AN INTEGRATED ANALYSIS OF FOUR TARGETED THORIUM CONJUGATES TO ASSESS THE TH-227 AND RA-223 DISTRIBUTION AND TISSUE-RELATED RADIATION.
Favorite
PII-026
AN INTEGRATED PK/PD MODELING FRAMEWORK OF NONCLINICAL EFFICACY AND CLINICAL HEMATOLOGICAL SAFETY TO INFORM DOSE SELECTION OF ATRI TUVUSERTIB IN COMBINATION WITH NIRAPARIB IN PATIENTS WITH PARPI-RESISTANT OVARIAN CANCER
Favorite
PI-057
AN INVESTIGATION INTO THE DOSE-DEPENDENT FOOD-EFFECT FOR DRUGS.
Favorite
PII-110
AN OVERVIEW OF FOOD EFFECT STUDIES IN PEDIATRIC POPULATION SUBMITTED TO U.S. FOOD AND DRUG ADMINISTRATION (FDA) (2004-2024)
Favorite
PII-042
ANALYSIS OF A CLINICAL PROGRAM TO RETURN CLINICALLY ACTIONABLE PHARMACOGENETIC INFORMATION FROM GERMLINE DNA SEQUENCING DATA GENERATED IN MOLECULAR TUMOR BOARDS: WORKFLOW AND ESTIMATED COSTS
Favorite
PI-094
ANALYZING AND INTEGRATING POSTPARTUM PHYSIOLOGICAL CHANGES IN LACTATING WOMEN.
Favorite
PI-126
APPLICATION OF MACHINE LEARNING TO GUIDE OPTIMAL FORMULATION SELECTION IN EARLY-STAGE DRUG DISCOVERY
Favorite
PI-002
APPLICATION OF VIRTUAL TWIN PBPK MODELS IN OBESE WITH CYP3A4 PHENOTYPING USING ENDOGENOUS BIOMARKER DATA.
Favorite
PII-002
APPLICATIONS AND LIMITATIONS OF 4ΒETA-HYDROXYCHOLESTEROL AS A SENSITIVE ENDOGENOUS BIOMARKER
Favorite
OAII-003
APPLYING ARTIFICIAL INTELLIGENCE-BASED DIGITAL TWINS IN TUBERCULOSIS CLINICAL TRIALS
Favorite
PT-019
APPLYING ARTIFICIAL INTELLIGENCE-BASED DIGITAL TWINS IN TUBERCULOSIS CLINICAL TRIALS
Favorite
PI-116
APPRAISAL OF PHARMACODYNAMIC CLAMP STUDY DESIGN FOR GLP-1 RECEPTOR AGONISTS.
Favorite
PII-058
APPROACHES TO HANDLING MISSING DOSING IN POPULATION PHARMACOKINETIC MODELING DUE TO NON-ADHERENCE
Favorite
PI-042
AREAS OF CLINICAL RELEVANCE AND PHARMACOGENE ACTIONABILITY FOR PATIENTS FROM A PHARMACIST-LED, VIRTUAL PHARMACOGENETICS CONSULTATION CLINIC.
Favorite
PI-027
ASSESSING BASELINE AND LONGITUDINAL CIRCULATING TUMOR DNA WITH PROGRESSION FREE SURVIVAL (PFS) IN BRAF V600E MUTANT (BRAFM) METASTATIC COLORECTAL CANCER (MCRC).
Favorite
LB-017
ASSESSING THE IMPACT OF AGE ON CANNABINOID DISPOSITION
Favorite
PI-009
ASSESSMENT OF KNOWLEDGE AND PERCEPTION OF CAR-T CELL THERAPY AMONG HEALTHCARE PROVIDERS IN SAUDI ARABIA
Favorite
PII-095
ASSESSMENT OF THE IMPACT OF NON-COMPARABLE IN VITRO ALCOHOL DOSE DUMPING RELEASE ON SYSTEMIC EXPOSURE USING PBPK ABSORPTION MODELING FOR TOPIRAMATE EXTENDED-RELEASE CAPSULES.
Favorite
PII-095
ASSESSMENT OF THE IMPACT OF NON-COMPARABLE IN VITRO ALCOHOL DOSE DUMPING RELEASE ON SYSTEMIC EXPOSURE USING PBPK ABSORPTION MODELING FOR TOPIRAMATE EXTENDED-RELEASE CAPSULES.
Favorite
PII-059
ASSESSMET OF SUBCUTANEOUS SITE OF INJECTION ON THE PK OF SOTATERCEPT
Favorite
PII-043
ASSOCIATION BETWEEN CYP2D6 GENOTYPE-INHIBITOR INTERACTIONS AND PAIN-RELATED EMERGENCY DEPARTMENT VISITS IN CYP2D6-OPIOID-TREATED PATIENTS
Favorite
LB-002
ASSOCIATION BETWEEN TREATMENT FOR MULTIPLE SCLEROSIS IN PREGNANCY AND PRECONCPETION PERIODS AND FETAL OUTCOMES - A REAL-WORLD RETROSPECTIVE COHORT STUDY
Favorite
PI-043
ATORVASTATIN AS A CARDIOPROTECTIVE AGENT AGAINST CARFILZOMIB-INDUCED CARDIOTOXICITY IN HUMAN INDUCED PLURIPOTENT STEM CELL-DERIVED CARDIOMYOCYTES.
Favorite
